ScreenerHero

NRSNNeuroSense Therapeutics Ltd. Ordinary Shares

NAS · US · Healthcare · Biotechnology · neurosense-tx.com
0.3763USDMkt Cap: 14.21M $P/E: —

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap14.21M $
Enterprise Value12.39M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-11.13M $
Revenue/Share—
Last Price0.3763 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees17
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.43
PEG—
EV/EBITDA-1.12
EV/Revenue—
P/S—
P/B-7.30
EPS (TTM)-0.39
EPS (Forward)-0.82
52W Range
0.351265% of range0.3900
52W High0.3900 USD
52W Low0.3512 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE713.14%
ROA-1082.20%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.67M $
CapEx (TTM)8.00K $
FCF Margin—
FCF Yield-27.23%
Net Debt4.00K $
Net Debt/EBITDA-0.00
Balance Sheet
Debt/Equity-0.11
Current Ratio0.31
Quick Ratio0.08
Book Value/Sh-0.0480 USD
Cash/Share0.0050 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)6.500 USD
Upside (mean)+1627.3%
Target Range3.000 USD – 9.000 USD
$3.000+1627.3% to mean$9.000
# Analysts3
Ownership
Shares Out.37.77M
Float23.87M
Insiders25.65%
Institutions0.89%
Short Interest
Short Ratio2.0d
Short % Float1.85%
Short % Out.1.45%
Shares Short548.05K
Short (prev mo.)585.03K
Technical
SMA 500.6322 (-40.5%)
SMA 2000.8224 (-54.2%)
Beta1.60
S&P 52W Chg21.00%
Avg Vol (30d)127.36K
Avg Vol (10d)347.55K
Technical Indicators
RSI (14)28.5
MACD-0.0702
MACD Signal-0.0652
MACD Hist.-0.0050
BB Upper0.5893 USD
BB Middle0.4680 USD
BB Lower0.3466 USD
BB Width51.87%
ATR (14)0.0740 USD
Vol Ratio (20d)0.27x